The United States is the largest national market for dorsomorphin dihydrochloride in North America, driven by its widespread use as a research-use-only small-molecule inhibitor of AMPK and BMP type I receptors. The compound is heavily used in stem cell and iPSC research, particularly in neural induction protocols, as well as in metabolic, cardiovascular, and cancer studies. Strong NIH and...